|
|
|
|
||
Re: Huge call by BMY on partner XLRN Luspatercept As an XLRN shareholder that would be a theft! Luspatercept is in anaemia what revlimid is in myeloma. Moreover today BMY just announced that luspatercept will be looked into in other diseases. Luspatercept potential could be mega but yet not fully understood/ appreciated by us who are not privy to what BMY is seeing. So lets hope no buyout for now. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
1161 | Re: Huge call by BMY on partner XLRN Luspatercept | stockmd | 3 | 12/9/2019 10:52:59 AM |